Skip to content
Inciteful Med

Treatment Options for SFT

Last updated:

Complete surgical removal with negative margins is the primary treatment for localized Solitary Fibrous Tumor (SFT). For advanced or unresectable cases, doctors often use anti-angiogenic drugs like Pazopanib or combination therapies to control tumor growth, as standard chemotherapy is less effective.

Key Takeaways

  • • Complete surgical removal with negative margins is the gold standard for localized SFT.
  • • Pre-operative embolization is often used to reduce bleeding risk in these vascular tumors.
  • • Radiation therapy is reserved for high-risk cases or when complete surgical removal isn't possible.
  • • Targeted therapies like Pazopanib are often preferred over traditional chemotherapy for advanced SFT.
  • • Active surveillance is rarely recommended unless surgery poses a significant safety risk.

Managing a Solitary Fibrous Tumor (SFT) requires a personalized plan. Because these tumors are rare and highly vascular (filled with blood vessels), treatment often involves a specialized multidisciplinary team. It is highly recommended to see a Sarcoma Specialist, as they have the specific expertise needed for this rare tumor type.

Surgery: The Primary Treatment

Surgery is the cornerstone of treatment for localized SFT [1][2]. The primary goal is Gross Total Resection (GTR)—removing the entire tumor along with a small “margin” of healthy tissue around it [3][4].

  • Why Complete Resection Matters: Achieving “negative margins” (no tumor cells at the edge of the removed tissue) is the best way to prevent the tumor from coming back [4][5].
  • Surgical Challenges: Because SFTs are rich in blood vessels, surgeons sometimes perform a procedure called embolization (blocking the tumor’s blood supply) shortly before surgery to reduce the risk of bleeding [6].

Radiation Therapy

Radiation uses high-energy beams to kill tumor cells. It is not always necessary, but it is frequently used in specific situations [7]:

  • High-Risk Tumors: If a tumor is classified as WHO Grade 3 or has high-risk features on the Demicco scale, radiation may be used after surgery (adjuvant) to lower the risk of local recurrence [8][9].
  • Incomplete Removal: If the surgeon cannot remove the entire tumor (subtotal resection), radiation is often the standard “mop-up” treatment for the remaining tissue [10][11].

Systemic Therapies for Advanced Disease

If an SFT has spread (metastatized) or cannot be safely removed by surgery, doctors use systemic medications.

Anti-Angiogenic Drugs (Targeted Therapy)
SFTs are very vascular, meaning they rely on new blood vessels to grow. Because of this, anti-angiogenic drugs like Pazopanib or Sunitinib are often preferred options [12][13]. These drugs work by “starving” the tumor of its blood supply. Pazopanib, for instance, has shown high disease control rates in advanced SFT [14][15].

Temozolomide and Bevacizumab
A common and effective combination therapy for SFT is Temozolomide (an oral chemotherapy drug) and Bevacizumab (an antibody that targets blood vessels) [16]. This “Temo/Bev” regimen is widely used for progressive SFT and has shown good results in stabilizing the disease [17][16].

Trabectedin
Trabectedin is another systemic option, often used as a second- or third-line treatment [18]. It works differently by interfering with the tumor’s DNA and its microenvironment [18].

Traditional Chemotherapy
Standard chemotherapy (like Doxorubicin) is less commonly used for typical SFT than for other sarcomas because SFTs often do not respond as well to it [12]. However, it may still be considered for very aggressive or high-grade forms of the disease where rapid tumor shrinkage is needed [13].

“Watch and Wait” (Active Surveillance)

In very rare cases, a “watch and wait” approach may be considered [19]. This involves monitoring the tumor with regular MRI or CT scans rather than treating it immediately. This is usually only an option if the tumor is:

  • Small and not causing any symptoms.
  • Growing very slowly.
  • Located in a spot where surgery would be extremely risky [19].

However, because SFTs can sometimes grow suddenly or change behavior, most doctors prefer to remove them if it is safe to do so [20].

Frequently Asked Questions

What is the primary treatment for Solitary Fibrous Tumor (SFT)?
Surgery, specifically Gross Total Resection (GTR), is the main treatment for localized SFT. The goal is to remove the entire tumor along with a margin of healthy tissue to prevent it from coming back.
When is radiation therapy necessary for SFT?
Radiation is typically used if the tumor is high-grade, has high-risk features, or could not be completely removed during surgery. It helps kill remaining tumor cells and lowers the risk of the cancer returning in the same spot.
What medications treat advanced or metastatic SFT?
Doctors often prescribe anti-angiogenic drugs like Pazopanib or Sunitinib, which starve the tumor of its blood supply. Another common option is a combination of Temozolomide and Bevacizumab, which has shown success in stabilizing the disease.
Why would I need embolization before SFT surgery?
Embolization is a procedure done shortly before surgery to block the tumor's blood supply. Since SFTs are very vascular (full of blood vessels), this helps reduce the risk of severe bleeding during the operation.
Can we just watch the tumor instead of treating it?
Active surveillance, or 'watch and wait,' is rare and usually reserved for small, slow-growing tumors that aren't causing symptoms, especially if surgery would be very risky. Most doctors prefer to remove SFTs because they can change behavior unpredictably.

Questions for Your Doctor

  • • Were you able to achieve a 'Gross Total Resection' with negative surgical margins?
  • • Based on my tumor's grade and the success of the surgery, is adjuvant radiation recommended to reduce my recurrence risk?
  • • If the tumor cannot be fully removed, would I be a candidate for anti-angiogenic drugs like Pazopanib?
  • • How do the side effects of targeted therapies like Pazopanib compare to traditional chemotherapy?
  • • If my tumor is currently small and not causing symptoms, is 'active surveillance' (watch and wait) an option for me?

Questions for You

  • • Was your surgery done through a traditional open incision or a minimally invasive method like VATS?
  • • Are you experiencing any new or worsening symptoms since your surgery that we should discuss with your care team?
  • • How do you feel about the possibility of long-term monitoring or 'watch and wait' if the tumor is slow-growing?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Central nervous system solitary fibrous tumors: Case series in accordance with the WHO 2021 reclassification. Framework for patient surveillance.

    Matthijs V, Beckers R, Broecke CV, et al.

    Acta neurochirurgica 2024; (166(1)):414 doi:10.1007/s00701-024-06304-7.

    PMID: 39417883
  2. 2

    Liver Metastasis From Intracranial Hemangiopericytoma 8 Years After Initial Resection: Case Report.

    Hendrickson Rahmlow T, Kolagatla S, Mattingly K, et al.

    Journal of investigative medicine high impact case reports 2022; (10()):23247096221132244 doi:10.1177/23247096221132244.

    PMID: 36281561
  3. 3

    Clinical outcomes of intracranial solitary fibrous tumor and hemangiopericytoma: analysis according to the 2016 WHO classification of central nervous system tumors.

    Kim BS, Kim Y, Kong DS, et al.

    Journal of neurosurgery 2018; (129(6)):1384-1396.

    PMID: 29372881
  4. 4

    Giant intracranial congenital hemangiopericytoma/solitary fibrous tumor: A case report and literature review.

    Giakoumettis D, Nikas I, Stefanaki K, et al.

    Surgical neurology international 2019; (10()):75 doi:10.25259/SNI-85-2019.

    PMID: 31528413
  5. 5

    Surgical management of spinal solitary fibrous tumor/hemangiopericytoma: a case series of 20 patients.

    Jia Q, Zhou Z, Zhang D, et al.

    European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 2018; (27(4)):891-901 doi:10.1007/s00586-017-5376-0.

    PMID: 29127512
  6. 6

    Solitary fibrous tumor of the orbit.

    Gupta S, Verma R, Sen R, et al.

    Asian journal of neurosurgery 2016; (11(1)):78 doi:10.4103/1793-5482.165804.

    PMID: 26889300
  7. 7

    Intracranial anaplastic hemangiopericytoma presenting with simultaneous extra-cranial metastases: A case report and review of the literature.

    Reddy S, Plitt A, Raisanen J, et al.

    Surgical neurology international 2019; (10()):148 doi:10.25259/SNI_111_2019.

    PMID: 31528483
  8. 8

    Solitary fibrous tumor of the pineal region with delayed ectopic intracranial metastasis: A case report and review of the literature.

    Wang Y, Zhang J, Liu Q, et al.

    Medicine 2019; (98(21)):e15737 doi:10.1097/MD.0000000000015737.

    PMID: 31124953
  9. 9

    Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy?

    Haas RL, Walraven I, Lecointe-Artzner E, et al.

    Acta oncologica (Stockholm, Sweden) 2021; (60(1)):35-41 doi:10.1080/0284186X.2020.1826574.

    PMID: 32988268
  10. 10

    Diagnosis and treatment of solitary fibrous tumor/hemangiopericytoma of central nervous system. Retrospective report of 17 patients and literature review.

    Ma L, Wang L, Fang X, et al.

    Neuro endocrinology letters 2018; (39(2)):88-94.

    PMID: 30183202
  11. 11

    Intracranial Solitary Fibrous Tumor: A "New" Challenge for PET Radiopharmaceuticals.

    Sardaro A, Mammucci P, Pisani AR, et al.

    Journal of clinical medicine 2022; (11(16)) doi:10.3390/jcm11164746.

    PMID: 36012988
  12. 12

    Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience.

    DeVito N, Henderson E, Han G, et al.

    PloS one 2015; (10(10)):e0140362 doi:10.1371/journal.pone.0140362.

    PMID: 26469269
  13. 13

    A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons.

    Martin-Broto J, Mondaza-Hernandez JL, Moura DS, Hindi N

    Cancers 2021; (13(12)) doi:10.3390/cancers13122913.

    PMID: 34200924
  14. 14

    Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor.

    Ebata T, Shimoi T, Bun S, et al.

    Oncology 2018; (94(6)):340-344 doi:10.1159/000486623.

    PMID: 29614488
  15. 15

    Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.

    Oh CR, Hong JY, Kim JH, et al.

    Targeted oncology 2020; (15(4)):485-493 doi:10.1007/s11523-020-00731-z.

    PMID: 32607656
  16. 16

    Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review.

    Maeda O, Ohka F, Maesawa S, et al.

    Nagoya journal of medical science 2020; (82(4)):631-644 doi:10.18999/nagjms.82.4.631.

    PMID: 33311794
  17. 17

    Recurrent Severe Hypoinsulinemic Hypoglycemia Responsive to Temozolomide and Bevacizumab in a Patient With Doege-Potter Syndrome.

    Ogunsakin AA, Hilsenbeck HL, Portnoy DC, Nyenwe EA

    The American journal of the medical sciences 2018; (356(2)):181-184 doi:10.1016/j.amjms.2018.01.008.

    PMID: 30219161
  18. 18

    Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.

    Khalifa J, Ouali M, Chaltiel L, et al.

    BMC cancer 2015; (15()):700 doi:10.1186/s12885-015-1697-8.

    PMID: 26472661
  19. 19

    The Natural History of Parapharyngeal Solitary Fibrous Tumor/Hemangiopericytoma: A Case Report.

    Xu M, Chen M, Hua H, et al.

    Ear, nose, & throat journal 2023; (102(2)):NP76-NP81 doi:10.1177/0145561321991338.

    PMID: 33530739
  20. 20

    Solitary Fibrous Tumor of the Mandible.

    Fonsêca TC, Agostini M, Paes JV, et al.

    Head and neck pathology 2024; (18(1)):124 doi:10.1007/s12105-024-01731-5.

    PMID: 39589596

This guide outlines standard treatment options for Solitary Fibrous Tumor for educational purposes. Treatment plans are highly personalized; always consult a sarcoma specialist for advice specific to your case.

Stay up to date

Get notified when new research about Solitary Fibrous Tumor (SFT) is published.

No spam. Unsubscribe anytime.